Abstract
Expansion of lung transplantation is limited by donor availability and donation after circulatory death (DCD) has attempted to address this shortage. Unfortunately, the uncontrolled recovery process does not result in a uniform donor allograft and the downsides of primary graft dysfunction (PGD) are large. Ex vivo lung perfusion (EVLP) affords the ability to evaluate and resuscitate lung donor allografts prior to transplantation. We sought to evaluate the efficacy and outcomes of EVLP and DCD lung donor allografts in a large, multicenter clinical trial (NOVEL Extension).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
